학술논문
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
Document Type
Article
Author
Source
In ESMO Open October 2022 7(5)
Subject
Language
ISSN
2059-7029